Patents Assigned to NGM Biopharmaceuticals, Inc.
  • Compositions and methods of use for treating metabolic disorders
    Patent number: 10195250
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: February 5, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Darrin Anthony Lindhout, Peng Zhang, Thomas Frederick Parsons
  • Binding proteins and methods of use thereof
    Patent number: 10174119
    Abstract: The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: January 8, 2019
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Wenyan Shen, Jie Tang, Yan Wang, Hugo Matern
  • Beta-klotho binding proteins
    Patent number: 10093735
    Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: October 9, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen
  • Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
    Patent number: 10071139
    Abstract: Methods and compositions for reducing one or more of triglyceride levels, total cholesterol levels and LDL cholesterol levels in a subject are provided. The methods include administering a fragment of ANGPTL8 to a subject having or at risk of developing elevated triglyceride levels, elevated total cholesterol levels and/or elevated LDL cholesterol levels.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: September 11, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Zhonghao Liu, Xunshan Ding
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasis
    Patent number: 9974833
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: May 22, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for reducing glucose levels in a subject
    Patent number: 9963494
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: May 8, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis
    Patent number: 9925242
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FG-F21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: March 27, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Compositions and methods of use for treating metabolic disorders
    Patent number: 9920118
    Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: March 20, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Wenyan Shen, Darrin Anthony Lindhout, Raj Haldankar, Hugo Matern
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasis
    Patent number: 9895416
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 20, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitis
    Patent number: 9889178
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 13, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitis
    Patent number: 9889177
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: February 13, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorption
    Patent number: 9878008
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: January 30, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesis
    Patent number: 9878009
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as bile acid homeostasis modulating activity, and methods for and uses in treatment of bile acid and other disorders.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: January 30, 2018
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Jian Luo
  • Compositions and methods of use for treating metabolic disorders
    Patent number: 9834586
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: December 5, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Darrin Anthony Lindhout, Raj Haldankar, Hui Tian, Jer-Yuan Hsu
  • Compositions and methods of use for treating metabolic disorders
    Patent number: 9828415
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: November 28, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar, Geoffrey Horner
  • Compositions and methods of use for treating metabolic disorders
    Patent number: 9827291
    Abstract: Methods of treating individuals with a glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: November 28, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Hugo Matern, Darrin Anthony Lindhout, Raj Haldankar
  • Methods of using compositions comprising fusion variants of FGF19 polypeptides for reducing glucose levels in a subject
    Patent number: 9751924
    Abstract: The invention relates to methods for and uses in reducing glucose levels in subjects in need thereof with variants and fusions of fibroblast growth factor 19 (FGF19) proteins and peptide sequences (and peptidomimetics).
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: September 5, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Beta klotho binding proteins and methods of use thereof
    Patent number: 9738716
    Abstract: The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 22, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Kalyani Mondal, Betty Chan Li, Yu Chen, Taruna Arora, Hugo Matern, Wenyan Shen
  • Compositions comprising fusion variants of FGF19 polypeptides
    Patent number: 9670260
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: June 6, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout
  • Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of diabetes
    Patent number: 9580483
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: February 28, 2017
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Lei Ling, Darrin Anthony Lindhout